Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer
Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer
复制标题
DOI：
10.1111/j.1365-2559.2011.04143.x
复制
发表时间：
2012-06-01
期刊：
影响因子：
6.4
通讯作者：
Nakopoulou, Lydia
中科院分区：
文献类型：
--
作者：
Magkou, Christina;Giannopoulou, Ioanna;Nakopoulou, Lydia
Magkou C，Giannopoulou I，Theohari I，Fytou A，Rafaillian P，Nomikos A，Papadimitriou C & Nakopoulou L？（2012）Histopiology similar to 60，11251132 Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with the invasive breast cancer目的：STAT-1是信号转导子和转录激活子（STAT）家族的第一个成员。在乳腺癌实验模型中，已经证明了凋亡和抗增殖作用。我们的目的是研究磷酸化STAT-1（pSTAT-1）在浸润性乳腺癌中的作用及其在绝经前后患者中的预后意义。方法与结果：采用免疫组化法检测165例乳腺癌组织中pSTAT-1的表达及其与雌激素受体（ER）、孕激素受体（PR）、caspase-3、pAkt的相关性。pSTAT-1阳性表达率为11.6%，主要定位于癌细胞胞浆。在绝经前患者中，胞浆pSTAT-1与分期（P = 0.014）、ER（P = 0.008）、caspase-3（P = 0.029）和pAkt（P = 0.045）正相关。单因素分析显示，胞浆pSTAT-1与总生存率低相关（P = 0.042），pSTAT-1/ER或PR共表达表型与无病生存率短相关（P = 0.012）。相反，在绝经后患者中，除了pSTAT-1/ER或PR共表达与较长的无病生存期的关系（P = 0.034）外，未观察到与临床病理参数和生存期的相关性。结论：这是第一个研究pSTAT-1在绝经前和绝经后妇女浸润性乳腺癌中的作用。我们的研究结果表明，pSTAT-1与绝经前患者的肿瘤进展有关，通过晚期和更差的生存率。
Magkou C, Giannopoulou I, Theohari I, Fytou A, Rafailidis P, Nomikos A, Papadimitriou C & Nakopoulou L ?(2012) Histopathology similar to 60, 11251132 Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer Aims: STAT-1 is the first member of the family of signal transducers and activators of transcription (STATs). In breast cancer experimental models, an apoptotic and antiproliferative effect has been demonstrated. Our aim was to study the role of phosphorylated STAT-1 (pSTAT-1) in invasive breast carcinoma and its prognostic significance in premenopausal and postmenopausal patients. Methods and results: Immunohistochemistry was performed in 165 patients in order to detect the expression of pSTAT-1 and its correlation with oestrogen receptor (ER), progesterone receptor (PR), caspase-3, and pAkt. pSTAT-1 was immunodetected in the cytoplasm of the malignant cells (11.6%). In premenopausal patients, cytoplasmic pSTAT-1 was positively correlated with stage (P = 0.014), ER (P = 0.008), caspase-3 (P = 0.029), and pAkt (P = 0.045). Univariate analysis showed that cytoplasmic pSTAT-1 was associated with poor overall survival (P = 0.042) and the phenotype of pSTAT-1/ER or PR coexpression with shorter disease-free survival (P = 0.012). In contrast, in postmenopausal patients, no association with clinicopathological parameters and survival was observed, except for the relationship of pSTAT-1/ER or PR coexpression with longer disease-free survival (P = 0.034). Conclusions: This is the first study examining the role of pSTAT-1 in premenopausal and postmenopausal women with invasive breast cancer. Our results suggest that pSTAT-1 is related to tumour progression in premenopausal patients through the advanced stage and worse survival.